Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Endocrine-Related Cancer|April 23, 2015
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumorsArvind Dasari, Alexandria Phan, Sanjay Gupta, et al.
Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitorsFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Annals of Surgical Oncology|April 8, 2018
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver MetastasesJordan M Cloyd, Kiyohiko Omichi, Takashi Mizuno, et al.
Oncotarget|April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerZhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Suyu Liu, Kangyu Lin, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2004
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgeryJing Jin, Zhongxing Liao, Zhen Zhang, et al.
Plos One|August 5, 2021
Mechanisms of socioeconomic differences in COVID-19 screening and hospitalizationsJarrod E Dalton, Douglas D Gunzler, Vardhmaan Jain, et al.
Oncotarget|April 23, 2021
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenibYehia I Mohamed, Sunyoung Lee, Lianchun Xiao, et al.
Pageof 7